Cure of hookworm infection with a cysteine protease inhibitor.
BACKGROUND
Hookworm disease is a major global health problem and principal among a number of soil-transmitted helminthiases (STHs) for the chronic disability inflicted that impacts both personal and societal productivity. Mass drug administration most often employs single-dose therapy with just two drugs of the same chemical class to which resistance is a growing concern. New chemical entities with the appropriate single-dose efficacy are needed.


RESULTS
Using various life-cycle stages of the hookworm Ancylostoma ceylanicum in vitro and a hamster model of infection, we report the potent, dose-dependent cidal activities of the peptidyl cysteine protease inhibitors (CPIs) K11002 (4-mopholino-carbonyl-phenylalanyl-homophenylalanyl- vinyl sulfone phenyl) and K11777 (N-methylpiperazine-phenylalanyl-homophenylalanyl-vinylsulfone phenyl). The latter is in late pre-clinical testing for submission as an Investigational New Drug (IND) with the US Federal Drug Administration as an anti-chagasic. In vitro, K11002 killed hookworm eggs but was without activity against first-stage larvae. The reverse was true for K11777 with a larvicidal potency equal to that of the current anti-hookworm drug, albendazole (ABZ). Both CPIs produced morbidity in ex vivo adult hookworms with the activity of K11777 again being at least the equivalent of ABZ. Combinations of either CPI with ABZ enhanced morbidity compared to single compounds. Strikingly, oral treatment of infected hamsters with 100 mg/kg K11777 b.i.d. (i.e., a total daily dose of 200 mg/kg) for one day cured infection: a single 100 mg/kg treatment removed >90% of worms. Treatment also reversed the otherwise fatal decrease in blood hemoglobin levels and body weights of hosts. Consistent with its mechanism of action, K11777 decreased by >95% the resident CP activity in parasites harvested from hamsters 8 h post-treatment with a single 100 mg/kg oral dose.


CONCLUSIONS
A new, oral single-dose anthelmintic that is active in an animal model of hookworm infection and that possesses a distinct mechanism of action from current anthelmintics is discovered. The data highlight both the possibility of repurposing the anti-chagasic K11777 as a treatment for hookworm infection and the opportunity to further develop CPIs as a novel anthelmintic class to target hookworms and, possibly, other helminths.
Department of Pediatrics, Section of Infectious Diseases, Yale University School of Medicine, New Haven, Connecticut, USA.
Jon J
JJ
Vermeire
Lorine D
LD
Lantz
Conor R
CR
Caffrey
D000284:Administration, Oral; D000722:Ancylostoma / Q000187:drug effects / Q000472:pathogenicity; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage* / Q000494:pharmacology; D006224:Cricetinae; D015853:Cysteine Proteinase Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology; D004151:Dipeptides / Q000008:administration & dosage* / Q000494:pharmacology; D004195:Disease Models, Animal; D005260:Female; D006725:Hookworm Infections / Q000188:drug therapy*; D007814:Larva / Q000187:drug effects; D008297:Male; D008647:Mesocricetus; D010649:Phenylalanine / Q000031:analogs & derivatives; D010879:Piperazines; D013450:Sulfones / Q000008:administration & dosage* / Q000494:pharmacology; D016019:Survival Analysis; D014105:Tosyl Compounds; D016896:Treatment Outcome; D014753:Vinyl Compounds / Q000008:administration & dosage* / Q000494:pharmacology; D015053:Zygote / Q000187:drug effects
D000871:Anthelmintics; D015853:Cysteine Proteinase Inhibitors; D004151:Dipeptides; D010879:Piperazines; D013450:Sulfones; D014105:Tosyl Compounds; D014753:Vinyl Compounds; C115125:morpholin- urea-phenylalanyl-homophenylalanyl-vinylsulfone-phenyl; C487484:N-pip-phenylalanine-homophenylalanine-vinyl sulfone phenyl; D010649:Phenylalanine